The FDA granted approval to Lilly’s oral SERD imlunestrant, expanding its label from monotherapy to include combination use with its CDK4/6 inhibitor Verzenio.
The FDA granted approval to Lilly’s oral SERD imlunestrant, expanding its label from monotherapy to include combination use with its CDK4/6 inhibitor Verzenio.